ABSTRACT
Evidence from animal research, postmortem analyses, and MRI investigations indicate substantial morphological alteration in brain structure as a function of HIV or cocaine dependence (CD). Although previous research on HIV+ active cocaine users suggests the presence of deleterious morphological effects in excess of either condition alone, a yet unexplored question is whether there is a similar deleterious interaction in HIV+ individuals with CD who are currently abstinent. To this end, the combinatorial effects of HIV and CD history on regional brain volume, cortical thickness, and neurocognitive performance was examined across four groups of participants: healthy controls, HIV-negative individuals with a history of CD, HIV+ individuals with no history of CD, HIV+ individuals with a history of CD. Our analyses revealed no statistical evidence of an interaction between both conditions on brain morphometry and neurocognitive performance. While descriptively, individuals with comorbid HIV and a history of CD exhibited the lowest neurocognitive performance scores, using Principle Component Analysis of neurocognitive testing data, HIV was identified as a primary driver of neurocognitive impairment. Higher caudate volume was evident in CD+ participants relative to CD-participants. Taken together, these data provide evidence of independent effects of HIV and CD history on brain morphometry and neurocognitive performance in cocaine-abstinent individuals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Participant recruitment, phenotyping and neuroimaging/neurophysiology at the University of Rochester (UR) is conducted through cores of the UR Intellectual and Developmental Disabilities Research Center (UR IDDRC), which is supported by a center grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (P50 HD103536 to JJF). KMWs work on this project was supported in part by a graduate training fellowship (T32 AI049815) and pilot funds provided through the Center for AIDS Research at the University of Rochester with support from the National Institute of Allergy and Infectious Diseases (NIAID P30 AI078498).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Research Subjects Review Board at the University of Rochester (STUDY1081).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be made available upon reasonable request to the corresponding author.
